Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Zaleplon. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 known ✓ | P14867 | 1/20 | 0.98 |
| ▸ | GABRG2 known ✓ | P18507 | 1/20 | 0.98 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.98 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.98 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.98 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.98 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.98 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.98 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.98 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.44 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.43 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.38 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Zaleplon SCHEMBL29118 | 0.99 | KDM4E (1.00) | KDM4EMAPK1GABRA1GABRG2GABRB3 | |
| Zaleplon SCHEMBL5605771 | 0.99 | KDM4E (1.00) | KDM4EMAPK1GABRA1GABRG2GABRB3 | |
| Zaleplon SCHEMBL29375436 | 0.99 | KDM4E (1.00) | KDM4EMAPK1GABRA1GABRG2GABRB3 | |
| Zaleplon SCHEMBL4726630 | 0.98 | KDM4E (0.98) | KDM4EMAPK1GABRA1GABRG2GABRB3 | |
| Zaleplon SCHEMBL27637735 | 0.97 | KDM4E (0.96) | KDM4EMAPK1GABRA1GABRG2GABRB3 | |
| Zaleplon SCHEMBL4726658 | 0.95 | KDM4E (0.93) | KDM4EMAPK1GABRA1GABRG2GABRB3 | |
| Zaleplon SCHEMBL4726073 | 0.95 | KDM4E (0.93) | KDM4EMAPK1GABRA1GABRG2GABRB3 | |
| SCHEMBL3166147 | 0.92 | KDM4E (0.87) | KDM4EMAPK1GABRA1GABRG2GABRB3 | |
| SCHEMBL3164210 | 0.91 | KDM4E (0.86) | KDM4EMAPK1GABRA1GABRG2GABRB3 | |
| SCHEMBL3168939 | 0.90 | KDM4E (0.84) | KDM4EMAPK1GABRA1GABRG2GABRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114729354-A | Small RNA medicine for preventing and treating inflammatory related diseases and combination thereof | 中国医学科学院基础医学研究所 | 2022-07-08 | — | — | CN | disclosed |
| CN-112789281-A | Tert-butyl (S) -2- (4- (phenyl) -6H-thieno [3,2-f ] [1,2,4] triazolo [4,3-a ] [1, 4] diazepin-6-yl) acetate derivatives and related compounds as bromodomain BRD4 inhibitors for the treatment of cancer | 豪夫迈·罗氏有限公司 | 2021-05-11 | — | — | CN | disclosed |
| CN-101370525-A | Dual variable domain immunoglobin and uses thereof | ABBOTT LAB (US) | 2009-02-18 | — | — | CN | disclosed |
| WO-2008024151-A2 | SALTS AND CO-CRYSTALS OF PYRAZOLOPYRIMIDINE COMPOUNDS, COMPOSITIONS THEREOF AND METHODS FOR THEIR PRODUCTION AND USE | DOV PHARMACEUTICAL, INC. (US) | 2008-02-28 | — | — | WO | disclosed |
| US-20080045547-A1 | Salts And Co-Crystals of Pyrazolopyrimidine Compounds, Compositions Thereof And Methods For Their Production And Use | DOV PHARMACEUTICAL, INC. | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045547-A1 | Salts And Co-Crystals of Pyrazolopyrimidine Compounds, Compositions Thereof And Methods For Their Production And Use | PNPO, INPP5A, P2RY6 | GABRA1 3469/4885GABRG2 3521/4885KDM4E 4391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.